News
The first UB Science Festival brings research closer to citizens
La UB divulgaorganises the firstUB Science Festival, an activity that opens the doors of the University of Barcelona and bring citizens closer to the research activity developed at the University in an amusing and innovative way. The festival takes place on Friday 22 May, from 10 a.m. to 7 p.m. Different science dissemination activities —a […]
Five years driving innovation at IDIBELL
On May 4, the small hall of the University Hospital of Bellvitge hosted a training seminar on intellectual property in the field of Health in charge of patent agency Herrero & Asociados. During the day, the head of the IDIBELL Innovation Unit, Montse Ballarin, presented the results achieved since it was launched five years ago. […]
Researchers raise funds against cancer at the AECC collection day
Under the slogan “You cannot imagine what a euro launches” last May 6, the Spanish Association Against Cancer (AECC) took to the streets to raise funds for cancer research. Marquee AECC at Barcelona downtown became a laboratory where researchers from IDIBELL and Valle Hebron Research Institute (VHIR) could answer questions from citizens about how cancer […]
Manel Esteller and Xavier Gómez-Batiste received Josep Trueta health merit medal
The director of the Epigenetics and Cancer Biology of IDIBELL, Manel Esteller and the responsible of Qualy Observatory of the Catalan Institute of Oncology (ICO) and head of the research group on palliative care at IDIBELL, Xavier Gómez Batiste received the medal Josep Trueta to the sanitary merit of this year. The ceremony took place […]
¿Discovered the sixth DNA’s base?
Two more bases: the Methyl- cytosine and Methyl-adenine In bacteria and in complex organisms Article Article
A new and less toxic HIV drug
University Hospital of Bellvitge and IDIBELL have participated in an international study published in The Lancet that has evaluated a new drug with fewer negative long-term effects that one of the most used so far in treating HIV. Today, it would be beneficial for around 65% of patients with HIV The tenofovir disoproxil fumarate, one […]
